TSP2-based Non-Invasive Liver Fibrosis Diagnostics
We are currently seeking partners for:
-Collaborative development
-Technology licensing or assignment
For Contact:
Technology Transfer:
INNOVECTIS GmbH
Altenhöferallee 5
60438 Frankfurt am Main, Germany
Phone: +49 69 25 61 632-0
Kirstin.schilling@innovectis.de
Technology
This technology is a non-invasive serum biomarker platform designed to determine the stage of liver fibrosis and assess the speed of fibrosis progression.
It is based on thrombospondin-2 (TSP2) combined with additional protein markers and clinical chemistry variables, enabling algorithm-based interpretation from serum or plasma samples.
The platform uses validated immunoassays, including sandwich ELISAs for TSP2 and other matricellular markers such as IGFBP7, GDF15, TSP4 and CD163, with a strong analytical basis for transfer into diagnostic workflows.
In clinical studies, TSP2-based algorithms showed strong performance in identifying advanced fibrosis and at-risk MASH, and outperformed common
comparators in relevant cohorts.
Applications
-The technology can be used for patient stratification in liver fibrosis trials, treatment monitoring, and the assessment of fibrosis dynamics over time.
-It is especially relevant for identifying patients with significant fibrosis who may benefit from therapeutic intervention and for tracking treatment response in clinical practice or drug development settings.
-Its application potential extends across a broad range of fibrotic liver diseases, including MASH, PSC, PBC, post-transplant fibrosis, autoimmune hepatitis, and viral hepatitis B or C.
Technology stage
-The analytical basis of the platform has already been established through in-house validated sandwich ELISAs for TSP2, IGFBP7, CD163 and GDF15.
-Solid clinical evidence is available from large patient studies in MASH, PSC, PBC, hepatitis B/C, and post-transplant liver fibrosis progression.
